Tetracyclines

Antibiotic Discovery and Development

Volumn 9781461414001, Issue , 2012, Pages 147-179

  Bradford, Patricia A ^a   Jones, C Hal ^b  

^a ASTRAZENECA   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84949178245     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-1400-1_5     Document Type: Chapter

References (141)

1. Allen JC (1976) Minocycline. Ann Intern Med 85(4):482-487
2. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E (2008) Clinical and microbiological outcomes of serious infections with multidrug-resistant gramnegative organisms treated with tigecycline. Clin Infect Dis 46(4):567-570
3. Arbeit RD, Roberts JA, Forsyth, AR et al (2008) Safety and efficacy of PTK 0796: results of the phase 2 study in complicated skin and skin structure infections following IV and oral stepdown therapy. Abstract L-1515. 48th Interscience conference on antimicrob agents chemother, Washington, DC
4. Babinchak TE, Ellis-Gross J, Dartois N et al (2005) The efficacy and safety of tigecycline in the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(suppl 5):S354-S367
5. Backus EJ, Duggar BM, Campbell TH (1954) Variation in Streptomyces aureofaciens. Ann NY Acad Sci 60:86-101
6. Barbosa TM, Levy SB (2000) Differential expression of over 60 chromosomal genes in Escherichia coli by constitutive expression of MarA. J Bacteriol 182(12):3467-3474
7. Barrett JF (2005) Can biotech deliver new antibiotics? Curr Opin Microbiol 8:498-503
8. Bauer G, Berens C, Projan SJ, Hillen W (2004) Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 53(4):592-599
9. Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, Strick CA, Su WG, Sutcliffe J, Wondrack L (1996) Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 40(9):2226-2228
10. Blackwood RK, Beereboom JJ, Rennhard HH, Schach von Wittenau M, Stephens CR (1963) 6-Methylenetetracyclines. III. Preparation and properties. J Amer Chem Soc 85:3943-3953
11. Boothe JH, Kende AS, Fields TL, Wilkinson RG (1959) Total synthesis of tetracyclines. I. (+/-)-Dedimethylamino-12a-deoxy-6-demethylanhydrochlortetracycline. J Amer Chem Soc 81:1006-1007
12. Boucher HW, Wennersten CB, Eliopoulos GM (2000) In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 44(8):2225-2229
13. Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, Bradford PA (2005) In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002. Diagn Microbiol Infect Dis 51(4):291-295
14. Bradford PA, Petersen PJ, Young M et al (2005) Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase ro standardize the test method. Antimicrob Agents Chemother 49(9):3903-3909
15. Bradford PA, Weaver-Sands DT, Petersen PJ (2005) In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin Infect Dis 41(Suppl 5):S315-S332
16. Bradford PA, Petersen PJ, Tuckman M (2008) In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community acquired pneumonia. Clin Microbiol Infect 14(9):882-886
17. Bratu S, Mooty M, Nichani S et al (2005) Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 49(7):3018-3020
18. Bryskier A (2005) Tetracyclines. In: Bryskier A (ed) Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington, DC, pp 642-651
19. Capone A, D'Arezzo S, Visca P et al (2008) In vitro activity of tigecycline against multidrugresistant Acinetobacter baumannii. J Antimicrob Chemother 62(2):422-423
20. Castanheira M, Sader HS, Deshpande TR et al (2008) Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallobeta- lactamase-producing Enterobacteriaceae: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother 52(2):570-573
21. Centers for Disease Control and Prevention (2001) Update: investigation of bioterrorismrelated anthrax and interim guidelines for exposure management and antimicrobial therapy. MMWR Morb Mortal Wkly Rep 50:909-919
22. Chang TW, Weinsteing L (1962) A comparison of the in vitro and in vivo activity of methacycline and other tetracycline compounds. Antibiot Chemother 12:676-688
23. Chiyowski LN (1973) Effectiveness of antibiotics applied as postinoculation sprays against clover phyllody and aster yellows. J Plant Science 53:87-91
24. Chopra I, Hawkey PM, Hinton M (1992) Tetracyclines, molecular and clinical aspects. J Antimicrob Chemother 29(3):245-277
25. Church R, Schuab RE, Weiss MJ (1971) Synthesis of 7-dimethylamino-6-demethyl-6- deoxytetracycline (Minocycline) via 9-nitro-6-demethyl-6-deoxytetracycline. J Org Chem 36:723-725
26. CLSI (2005) Performance standards for antimicrobial susceptibility testing: M100-S15, fifteenth informational supplement. Clinical Laboratory Standards Institute, Wayne, PA
27. Curcio D, Fernandez F, Jones RN et al (2007) Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view. J Clin Microbiol 45(6):2095, author reply 2095-6
28. Dean CR, Visalli MA, Projan S (2003) Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47(3):972-978
29. Duggar BM (1905) The principles of mushroom growing and mushroom spawn-making. USDA Bur Plant Indus Bull 35:1-60
30. Duggar BM (1948) Aureomycin: a product of the continuing search for new antibiotics. Ann NY Acad Sci 51:171-181
31. Duggar BM (1949). Aureomycin and preparation of same. USA: 7 United States Patent 2482055
32. Dukart G, Dartois N, Cooper C et al (2008) Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. 308 Study Group; 313 Study Group. Diagn Microbiol Infect Dis 61(3):329-338
33. Ellis-Grosse E, Babinchak T, Dartois N et al (2005) The efficacy and safety of tigecycline in the treatment of skin and skin structure infections: results of two double-blind phase 3 comparison studies with vancomycin/aztreonam. Clin Infect Dis 41(suppl 5):S341-S353
34. Evans ME, Feola DJ, Rapp RP (1999) Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacolther 33:960-967
35. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333-1341
36. Felekidis A, Goblet-Stachow M, Liegeois JF et al (1997) Ligand effects in the hydrogenation of methacycline to doxycycline and epi-doxycycline catalyzed by rhodium complexes. Molecular structure of the key catalyst [closo-3,3-( h 2,3-C7H7CH2)-3,1,2-RhC2B9H11]. J Organometallic Chem 536-537:405-412
37. Findlay AC, Hobby GL, Pan SY et al (1950) Terramycin, a new antibiotic. Science 111:85
38. Fleming A (1929) FlemOn the antibacterial action of cultures to a Penicillium, with special reference to their use in the isolation of B. influenzae. Br J Exp Pathol 10:226-236
39. Fluit AC, Florijin A, Verhoef J et al (2005) Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 49(4):1636-1638
40. Fritsche TR, Sader HS, STilwell MG et al (2005) Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 52(3):187-193
41. Gales AC, Sader HS et al (2008) Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 60(4):421-427
42. Garau J (2008) Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 14(Suppl 1):198-202
43. George AM, Hall RM, Stokes HW (1995) Multidrug resistance in Klebsiella pneumoniae: a novel gene, ramA, confers a multidrug resistance phenotype in Escherichia coli. Microbiology 141(Pt 8):1909-1920
44. Golub LM, Sorsa T, Lee HM et al (1995) Doxycycline inhibits neutrophil (PMN)-type matrix metalloproteinases in human adult periodontitis gingiva. J Clin Periodontology 22:100-109
45. Guay GG, Tuckman M, Rothstein DM (1994) Mutations in the tetA(B) gene that cause a change in substrate specificity of the tetracycline efflux pump. Antimicrob Agents Chemother 38(4):857-860
46. Gupta SPK, Milford EL (1987) In quest of panacea: successes and failures of Yellapragada SubbaRow. Evelyn Publishers, New Delhi
47. Halstead DC, Abid J, Dowzicky MJ (2007) Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the tigecycline evaluation and surveillance trial. J Infect 55(1):49-57
48. Hirata T, Saito A, Nishino K et al (2004) Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 48(6): 2179-2184
49. Hoban D, Bouchillon S, Johnson B et al (2005) In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global tigecycline evaluation and surveillance trial (TEST Program 2004). Diagn Clin Immunol 52:215-227
50. Hochstein FA, Stephens CR, Conover LH et al (1952) Terramycin. VIII. The structure of terramycin. J Amer Chem Soc 74:3708-3709
51. Hochstein FA, Stephens CR, Conover LH et al (1953) Terramycin. X. The structure of terramycin. J Amer Chem Soc 75:5455-5475
52. Insa R, Cercenado E, Goyanes MJ et al (2007) In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 59(3):583-585
53. Johnson SE, Klein GC, Schmid GP et al (1984) Susceptibility of the lyme disease spirochete to seven antimicrobial agents. Yale J Biol Med 57(4):549-553
54. Jones RN, Anderegg TR, Sewson JM et al (2005) Quality control guidelines for testing gramnegative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. J Clin Microbiol 43:925-927
55. Jones RN, Biedenbach D, Fritsch EF et al (2006b) Activity of tigecycline tested against vancomycin- resistant Enterococcus faecium isolated in North America (NA) and Europe (EU), including clonal complex-17 (CC17) strains. Abstract E-749. 46th Interscience conference on antimicrobial agents and chemotherapy ASM, San Francisco
56. Jones RN, Ferraro MJ, Reller LB et al (2007) Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 45(1):227-230
57. Jones CH, Tuckman M, Howe AYM et al (2006) Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections. Antimicrob Agents Chemother 50(2):505-510
58. Jones CH, Tuckman M, Keeney D et al (2009) Characterization and sequence analysis of extended spectrum b -lactamase encoding genes from E. coli, K. pneumoniae, and P. mirabilis isolates collected during tigecycline phase 3 clinical trials. Antimicrob Agents Chemother 53(2):465-475
59. Keeney DA, Ruzin F, McAleese PA, Bradford (2008) MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in E. coli. J Antimicrob Chemother 61:46-53
60. Keeney D, Ruzin A, Bradford PA (2007) RamA, a transcriptional Regulator, and AcrAB, an RND-Type efflux Pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb Drug Resist 13(1):1-6
61. Keeney D, Ruzin A, McAleese F et al (2008) MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 61(1):46-53
62. Kenny GE, Cartwright FD (2001) Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and quinolones. Antimicrob Agents Chemother 45(9):2604-2608
63. Kumar A, Schweizer HP (2005) Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 57(10):1486-1513
64. Kuwahara-Arai K, Okuma K, Hanaki H et al (2002) Evaluation of in vitro antimicrobial activity of GAR-936 against community acquired MRSA (C-MRSA) and hospital acquired MRSA (H-MRSA) including strains resistant to vancomycin (VRSA or VISA). Abstracts of the 42nd ICAAC. American Society for Microbiology, San Diego, CA
65. Labthavikul P, Petersen PJ, Bradford PA (2003) In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother 47(12):3967-3969
66. Lakhssassi N, Elhajoui N, Lodter JP et al (2005) Antimicrobial susceptibility variation of 50 anaerobic periopathogens in aggressive periodontitis: an interindividual variability study. Oral Microbiol Immunol 20:244-252
67. Lolans K, Rice TW, Munoz-Price LS et al (2006) Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 50(9):2941-2945
68. Macone A, Donatelli J, Dumont T et al (2003) In vitro activity of PTK 0796 (BAY 73-6944) against gram-positive and gram-negative organisms. 43rd Interscience conference on antimicrobial agents and chemotherapy, Chicago, IL
69. Marchand I, Damier-Piolle L, Courvalin P et al (2004) Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 48(9):3298-3304
70. Martell MJJ, Boothe JH (1967) The 6-deoxytetracyclines. VII. Alkylated aminotetracyclines possessing unique antibacterial activity. J Med Chem 10:44-46
71. McAleese F, Murphy E, Babinchak T et al (2005) Use of ribotyping to retrospectively identify methicillin-resistant Staphylococcus aureus Isolates from phase 3 clinical trials for tigecycline that are genotypically related to community-associated isolates. Antimicrob Agents Chemother 49(11):4521-4529
72. McAleese F, Petersen P, Ruzin A et al (2005) A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 49(5):1865-1871
73. McCormick JRD, Sjolander NO, Hirsch U et al (1957) A new family of antibiotics: the demethyltetracyclines. J Amer Chem Soc 79:4561-4563
74. McCormick JRD, Sjolander NO, Johnson S et al (1959) Biosynthesis of tetracyclines. II. Simple defined media for growth of Streptomyces aureofaciens and elaboration of 7-chlorotetracycline. J Bacteriol 77:475-477
75. McCormick JRD, Hirsch U, Sjolander NO et al (1960) Cosynthesis fo tetracyclines by pairs of Streptomyces aureofaciens mutants. J Amer Chem Soc 82:5006-5007
76. McKenney D, Quinn JM, Jackson CL et al (2003a) The efficacy of PTK-0796 in murine models of Streptococcus pneumoniae infections. Abstract F-758. 43rd Interscience conference antimicrob agents chemother, Chicago, IL
77. McKenney D, Quinn JM, Jackson CL et al (2003b) Evaluation of PTK-0796 in experimental models of infections caused by gram-positive and gram-negative pathogens. Abstract F-757. 43rd Interscience conference antimicrob agents chemother, Chicago, IL
78. McMurray LM, Cullinane JC, Levy SB (1982) Transport of the lipophilic analog minocycline differs from that of tetracycline in susceptible and resistant Escherichia coli strains. Antimicrob Agents Chemother 22:791-799
79. Mendes RE, Sader HS, Deshpande L et al (2008) Antimicrobial activity of tigecycline against community-acquired methicillin-resistant Staphylococcus aureus isolates recovered from North American medical centers. Diagn Microbiol Infect Dis 60(4):433-436
80. Miller PA, McCormick JRD, Doershuk AP (1956) Studies of chlorotetracycline biosynthesis and the preparation of chlorotetracycline-C14. Science. Science 123:1030-1031
81. Morosini MI, Garcia-Castillo M, Coque TM et al (2006) Antibiotic coresistance in extendedspectrum- b -lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 50(8):2695-2699
82. Nadelman RB, Nowakowski J, Fish D et al (2001) Tick bite study group. Prophylaxis with single-dose doxycycline for the prevention of lyme disease after an Ixodes scapularis tick bite. N Engl J Med 345:79-84
83. Navon-Venezia S, Leavitt A, Carmeli Y (2007) High tigecycline resistance in multidrugresistant Acinetobacter baumannii. J Antimicrob Chemother 59(4):772-774
84. Niedercorn JG (1952) Process for producing aureomycin. United States Patent 2609329
85. Olson MW, Ruzin A, Feyfant E et al (2006) Functional, biophysical and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 50:2156-2166
86. Pearson M (1969) The million dollar bugs. Putnam, New York
87. Peleg AY, Potoski BA, Rea R et al (2007) Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother 59(1):128-131
88. Perlman D, Heuser LJ, Dutcher JD et al (1960) Biosynthesis of tetracycline by 5-hydroxytetracycline- producing cultures of Streptomyces rimosus. J Bacteriol 80:416-420
89. Petersen PJ, Bradford PA (2005) Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates. Antimicrob Agents Chemother 49(9):3910-3918
90. Petersen PJ, Jacobus NV, Weiss WJ et al (1999) In vitro and in vivo antimicrobial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 43(4):738-744
91. Pirotte B, Felekidis A, Fontaine M et al (1993) Stereoselective hydrogenation of methacycline to doxycycline catalyzed by rhodium-carbonate complexes. Tetrahedron Lett 34:1471-1474
92. Pliatsika V, Afkou Z, Protonotariou E et al (2007) In vitro activity of tigecycline against metallo- beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 60(6):1406-1407
93. Poole K (2004) Efflux-mediated multiresistance in gram-negative bacteria. Clin Microbiol Infect 10(1):12-26
94. Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56(1): 20-51
95. Raad I, Hanna H, Jiang Y et al (2007) Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 51(5):1656-1660
96. Ransmeier JC, Brown HE, Davis N (1951) Comparison of in vitro sensitivity of freshly isolated pathogenic bacteria to terramycin and other antibiotics. J Lab Clin Med 38(4): 620-630
97. Rasmussen BA, Gluzman Y, Tally FP (1994) Inhibition of protein synthesis occurring on tetracycline-resistant, tet-m protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 38(7):1658-1660
98. Retsema JA, Brennan LA, Girard AE (1991) Effects of environmental factors on the in vitro potency of azithromycin. Eur J Clin Microbiol Infect Dis 10(10):834-842
99. Ritacco FV, Haltli B, Janso JE (2003) Dereplication of Streptomyces soil isolates and detection of specific biosynthetic genes using an automated ribotyping instrument. J Indust Microbiol Biotech 30:472-479
100. Roblin PM, Hammerschlag MR (2000) In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 16:61-63
101. Keeney D, Ruzin A, Bradford PA (2007) RamA, a Transcriptional regulator, and AcrAB, a RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microbial Drug Resistance 13:1-6
102. Ruzin A, Keeney D, Bradford PA (2005) AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 49(2): 791-793
103. Ruzin A, Visalli MA, Keeney D et al (2005) Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 49(3):1017-1022
104. Ruzin A, Keeney D, Bradford PA (2007) AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Antimicrob Chemother 59(5):1001-1004
105. Ruzin A, Immermann FW, Bradford PA (2008) Real-time PCR and statistical analyses of acrAB and ramA expression in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 52(9):3430-3432
106. Ryan MJ, Lotvin JA, Fantini SE (1999) Cloning of the biosynthetic pathway for chlortetracycline and tetracycline formation and cosmids useful therein. United States Patent 5,589,385
107. Sader HS, Jones RN, Dowzicky MJ et al (2005) Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 52(3):203-208
108. Sader HS, Jones RN, Stilwell MG et al (2005) Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 52(3):181-186
109. Schafer JJ, Goff DA, Stevenson KB et al (2007) Early experience with tigecycline for ventilator- associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy 27(7):980-987
110. Schatz A, Waksman SA (1944) Effect of streptomycin and other antibiotic substances upon Mycobacterium tuberculosis and related organisms. Proc Soc Exp Biol Med 57:244-248
111. Schneiders T, Amyes SG, Levy SB (2003) Role of AcrR and ramA in fluoroquinolone resistance in clinical Klebsiella pneumoniae isolates from Singapore. Antimicrob Agents Chemother 47(9):2831-2837
112. Segal H, Garny S, Elisha BG (2005) Is IS(ABA-1) customized for acinetobacter? FEMS Microbiol Lett 243(2):425-429
113. Seifert H, Stefanik D, Wisplinghoff H (2006) Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 58(5):1099-1100
114. Shlaes DM (2006) An update on tetracyclines. Curr Opin Investig Drugs 7(2):167-171
115. Souli M, Kontopidou FV, Papadomichelakis E et al (2008) Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 46(6):847-854
116. Spangler SK, Appelbaum PC (1993) Oxyrase, a method which avoids carbon dioxide in the incubation atmosphere for anaerobic susceptibility testing of antibiotics affected by carbon dioxide. J Clin Microbiol 31(2):460-462
117. Stephens CR, Conover LH, Hochstein FA (1952) Terramycin. VII. Structure of aureomycin and terramycin. J Amer Chem Soc 74:4976-4977
118. Stephens CR, Conover LH, Hochstein FA et al (1952) Terramycin. VIII. structure of aureomycin and terramycin. J Amer Chem Soc 74:4976-4977
119. Stephens CR, Conover LH, Pasternak R et al (1954) The structure of aureomycin. J Amer Chem Soc 76:3568-3573
120. Stryjewski ME, Chambers HF (2008) Skin and soft-tissue infections caused by communityacquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 46(Suppl 5):S368-S377
121. Sum PE, Petersen P (1999) Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg Med Chem Lett 9(10): 1459-1462
122. Sum PE, Lee VJ, Testa RT (1994) Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 37(1):184-188
123. Swoboda S, Ober M, Hainer C et al (2008) Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 61(3):729-733
124. Taccone FS, Rodriguez-Villalobos H, De Backer D et al (2006) Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 25(4):257-260
125. Tally FT, Ellestad GA, Testa RT (1995) Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother 35(4):449-452
126. Testa R, Petersen P, Jacobus N et al (1993) In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 37(11):2270-2277
127. Thamlikitkul V, Tiengrim S, Tribuddharat C (2007) Comment on: high tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 60(1):177-178, author reply 178-9
128. Thomas JG, Metheny RJ, Karakiozis JM et al (1998) Long-term sub-antimicrobial doxycycline (Periostat) as adjunctive management in adult periodontitis: effects on subgingival bacterial population dynamics. Adv In Dental Res 12:32-39
129. Toon S, Rowland M (1979) Quantitative structure pharmacokinetic activity relation-ships with some tetracyclines. J Pharm Pharmacol 31(Suppl):43-47
130. Traczewski MM, Brown SD (2003) PTK 0796 (BAY 73-6944): in vitro potency and spectrum of activity compared to ten other antimicrobial compounds. 43rd Interscience conference on antimicrobial agents and chemotherapy, Chicago, IL
131. Tuckman M, Petersen PJ, Projan SJ (2000) Mutations in the interdomain loop region of the tetA(A) tetracycline resistance gene increase efflux of minocycline and glycylcyclines. Microb Drug Resist 6(4):277-282
132. Tuckman M, Keeney D, Camarda R et al. (2007a) Characterization and sequence analysis of extended spectrum beta-lactamase encoding genes from E. coli, K. pneumoniae, and P. mirabilis isolates collected during the tigecycline (TGC) phase 3 clinical trials; Abstract #C2- 2065. 47th Interscience conference on antimicrobial agents and chemotherapy: Abstract #C2-2065 ASM, Chicago, IL
133. Tuckman M, Petersen P, Howe AYM et al (2007) Occurence of tetracycline resistance genes among Escherichia coli isolates from the phase 3 clinical trials for tigecycline. Antimicrob Agents Chemother 51(9):3205-3211
134. Visalli MA, Murphy E, Projan SJ et al (2003) AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 47(2):665-669
135. Waites KB, Duffy LB, Dowzicky MJ (2006) Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 50(10):3479-3484
136. Wallace JR, Brown-Elliot BA, Crist CJ et al (2002) Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of Nontuberculous mycobacteria. Antimicrob Agents Chemother 46(10):3164-3167
137. Webster GF, Leyden JJ, McGinley KJ et al (1982) Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subminimal inhibitory concentrations of tetracycline, ampicillin, minocycline and erythromycin. AntimicrobAgents Chemotherapy 21:770-772
138. Wybo I, Pierard D, Verschraegen I et al (2007) Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 59(1):132-139
139. Wyeth Pharmaceuticals (2005) Tygacil™ [package insert]. Available at: http://www.fda.gov/cder/foi/label/2005/021821lbl.pdf. Accessed 20 June 2005
140. Zhanel GG, Palatnick L, Nichol KA et al (2003) Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian respiratory organism susceptibility study, 1997 to 2002. Antimicrob Agents Chemother 47(6):1867-1874
141. Ziv G, Sulman FG (1971) Analysis of pharmacokinetic properties of nine tetracycline analogs in dairy cows and ewes. Am J Vet Res 35:1197-1201